Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629991 · ClinicalTrials.gov registry record · Phase 2
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
A Phase 2 study of Prader-Willi Syndrome and Hyperphagia, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02629991 is a Phase 2 study of Prader-Willi Syndrome and Hyperphagia that has completed, run by Montefiore Medical Center. The registered enrollment target is 23 participants, below the 69-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02629991, a Phase 2 study of Prader-Willi Syndrome and Hyperphagia, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a randomized double-blind 8 week treatment trial of intranasal oxytocin (IN-OXT) vs. placebo in 24 subjects aged 5 to 18 years with PWS in order to assess IN-OXT's affect on (1) Eating behaviors (2) Repetitive and disruptive behaviors and (3) Salivary OXT levels.
Conditions Studied
Interventions
- DRUG Intranasal Oxytocin (IN-OXT)
- OTHER Matched Placebo
Study Locations (1)
New York
- Montefiore Medical Center, Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02629991
The ClinicalTrials.gov registry entry for NCT02629991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (67% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Intranasal Oxytocin (IN-OXT) is the first listed.
NCT02629991 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02629991 about?
NCT02629991 is a clinical study titled "Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome". The investigators propose a randomized double-blind 8 week treatment trial of intranasal oxytocin (IN-OXT) vs. placebo in 24 subjects aged 5 to 18 years with PWS in order to assess IN-OXT's affect on (1) Eating behaviors (2) Repetitive and disruptive behaviors and (3) Salivary OXT levels.
What is the current status of trial NCT02629991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-10. Estimated completion is 2018-05.
What conditions does trial NCT02629991 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome, Hyperphagia.
What interventions are being tested in trial NCT02629991?
The interventions under investigation include: Intranasal Oxytocin (IN-OXT) (DRUG), Matched Placebo (OTHER).
Who is sponsoring clinical trial NCT02629991?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02629991 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
COMPLETED · Phase 2
-
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
COMPLETED · Phase 2
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.